Preliminary results from two early-phase clinical trials suggest that the investigational drug ibrutinib may benefit some patients with an aggressive type of non-Hodgkin lymphoma (NHL). In the trials, some patients with diffuse large B-cell lymphoma (DLBCL) who did not respond to standard therapies, or who had stopped responding to these treatments, experienced complete or substantial tumor shrinkage after treatment with ibrutinib. The treatment was well tolerated, with only minor side effects.
Dr. Louis Staudt of NCI’s Center for Cancer Research (CCR), who co-led both trials, presented the findings April 1 at the 2012 American Association for Cancer Research annual meeting in Chicago. Read more > >
The director of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins University and an investigator with the Howard Hughes Medical Institute explains the potential and the limitations of whole-genome sequencing.
- Senate Appropriations Hearing Highlights NCI’s Provocative Questions Project
- FDA Takes Action under the Tobacco Control Act of 2009
- Cyber-Seminar will Explore Measuring the Health of a Community
- Dr. John Potter to Deliver First Schatzkin Lecture in Nutritional Epidemiology
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at email@example.com.